Catalyst Pharma Soars: Revenue Up 25%, Net Income Jumps 50%

TL;DR

CPRX is crushing it with FIRDAPSE and AGAMREE, making it a strong buy as they expand globally and boost their cash pile.

AI Summary

Catalyst Pharmaceuticals, Inc. (CPRX) reported robust financial performance for the nine months ended September 30, 2025, with total revenues increasing by 24.7% to $436.38 million from $349.91 million in the prior year. Product revenue, net, was the primary driver, growing to $436.31 million from $347.52 million. Net income saw a significant jump of 49.7% to $161.63 million, up from $107.95 million in the same period of 2024. Diluted EPS also rose substantially to $1.27 from $0.87. The company's cash and cash equivalents surged to $689.89 million as of September 30, 2025, from $517.55 million at December 31, 2024, largely due to $163.78 million in net cash provided by operating activities. Key business changes include the FDA approval in Q2 2024 to increase the maximum daily dose of FIRDAPSE to 100 mg and the commercial launch of AGAMREE in the U.S. on March 13, 2024. The company also expanded FIRDAPSE's commercial availability to Japan in January 2025 through a license agreement with DyDo Pharma, Inc. Risks include reliance on a limited product portfolio and the need for additional funding for future business development, despite current liquidity.

Why It Matters

This strong performance signals Catalyst Pharmaceuticals' successful strategy in expanding its rare disease portfolio and market reach, which is crucial for investors seeking growth in the biopharmaceutical sector. The commercial launch of AGAMREE and FIRDAPSE's label expansion and entry into the Japanese market demonstrate effective execution against competitive pressures. For employees, this growth suggests job stability and potential for further expansion. Customers benefit from increased access to specialized treatments like FIRDAPSE and AGAMREE. The broader market sees a growing player in the orphan drug space, potentially spurring further innovation and competition in rare disease treatments.

Risk Assessment

Risk Level: medium — The risk level is medium due to the company's reliance on a limited number of commercial-stage drug products (FIRDAPSE, AGAMREE, FYCOMPA) and the inherent risks of biopharmaceutical development and commercialization. While the company has a strong cash position of $689.89 million, it explicitly states it 'may seek to raise new capital to fund additional business development activities,' which could dilute current stockholders.

Analyst Insight

Investors should consider increasing their position in CPRX, given the significant revenue and net income growth, coupled with strategic market expansions for FIRDAPSE and the successful launch of AGAMREE. Monitor future business development activities for potential acquisitions that could further diversify the product pipeline and mitigate reliance on existing drugs.

Financial Highlights

revenue

$436.38M

net Income

$161.63M

eps

$1.27

cash Position

$689.89M

revenue Growth

+24.7%

Revenue Breakdown

Key Numbers

• $436.31M — Product revenue, net (Increased from $347.52M in 2024 for the nine months ended September 30, 2025, a 25.5% increase.)
• $161.63M — Net income (Increased from $107.95M in 2024 for the nine months ended September 30, 2025, a 49.7% increase.)
• $1.27 — Diluted net income per share (Increased from $0.87 in 2024 for the nine months ended September 30, 2025.)
• $689.89M — Cash and cash equivalents (As of September 30, 2025, up from $517.55M at December 31, 2024.)
• $163.78M — Net cash provided by operating activities (For the nine months ended September 30, 2025.)
• 122,912,387 — Shares of common stock outstanding (As of November 3, 2025.)
• $140.7M — Net proceeds from public offering (From 10 million shares of common stock on January 9, 2024.)
• 24.7% — Total revenue growth (For the nine months ended September 30, 2025, compared to the same period in 2024.)
• 49.7% — Net income growth (For the nine months ended September 30, 2025, compared to the same period in 2024.)
• 100 mg — Increased maximum daily dose of FIRDAPSE (Approved by FDA in Q2 2024 for adults and pediatric patients weighing more than 45 kg.)

Key Players & Entities

• CATALYST PHARMACEUTICALS, INC. (company) — registrant
• FIRDAPSE (company) — commercial-stage drug product
• AGAMREE (company) — commercial-stage drug product
• FYCOMPA (company) — commercial-stage drug product
• U.S. Food & Drug Administration (FDA) (regulator) — approved FIRDAPSE and AGAMREE
• KYE Pharmaceuticals, Inc. (company) — license and supply agreement for FIRDAPSE in Canada
• DyDo Pharma, Inc. (company) — license and supply agreement for FIRDAPSE in Japan
• Eisai Co., Ltd. (company) — seller of U.S. rights to FYCOMPA
• Santhera Pharmaceuticals Holdings (company) — seller of exclusive license for AGAMREE in North America
• NASDAQ Capital Market (regulator) — exchange where common stock is registered

FAQ

Risk Factors

• Reliance on Limited Product Portfolio [high — financial]: The company's revenue is heavily concentrated on FIRDAPSE and AGAMREE. Any adverse events, market shifts, or competitive pressures affecting these products could significantly impact financial results. The success of future product development and commercialization is critical.
• Need for Future Funding [medium — financial]: While current liquidity is strong with $689.89M in cash, future business development, research, and potential acquisitions may require additional funding. The ability to secure such funding on favorable terms is a potential risk.
• FDA Approval and Post-Market Surveillance [medium — regulatory]: The company relies on FDA approvals for its products, including the recent increase in FIRDAPSE's maximum daily dose to 100 mg. Post-market surveillance and adherence to regulatory requirements are crucial to maintain product status and avoid penalties.
• Market Acceptance of New Products [medium — market]: The commercial launch of AGAMREE in March 2024 and expansion of FIRDAPSE into Japan present opportunities but also risks related to market adoption, physician prescribing habits, and patient access in new territories.

Industry Context

Catalyst Pharmaceuticals operates in the rare disease pharmaceutical sector, characterized by high unmet medical needs and specialized patient populations. The industry is competitive, with companies focusing on developing and commercializing therapies for specific genetic disorders. Regulatory hurdles are significant, but successful drug launches can lead to substantial market share and profitability due to limited competition.

Regulatory Implications

The company's success is intrinsically linked to regulatory approvals and compliance. The FDA's approval of increased FIRDAPSE dosage and the commercialization of AGAMREE highlight the importance of regulatory pathways. Ongoing adherence to manufacturing standards, post-market surveillance, and reporting requirements are critical to maintain product status and avoid sanctions.

What Investors Should Do

1. Monitor AGAMREE's market penetration and revenue contribution.
2. Evaluate the impact of FIRDAPSE's expanded Japan market access.
3. Assess the company's R&D pipeline and business development activities.
4. Review cash burn rate and future funding needs.

Key Dates

• 2024-03-13: Commercial launch of AGAMREE in the U.S. — Introduces a new revenue stream and expands the company's product portfolio beyond FIRDAPSE.
• 2024-01-09: Net proceeds of $140.7M from public offering — Strengthened the company's balance sheet and provided capital for operations and growth initiatives.
• 2025-01: Expansion of FIRDAPSE commercial availability to Japan — Opens a new international market for a key product, diversifying revenue sources and increasing global reach.
• 2024-04-01: FDA approval to increase FIRDAPSE maximum daily dose to 100 mg — Enhances treatment options for patients and potentially increases product utilization and revenue.
• 2025-09-30: End of the nine-month period — Reporting period for the 10-Q, showing significant revenue and net income growth.

Glossary

Product revenue, net

Revenue generated from the sale of pharmaceutical products after deducting allowances, discounts, and returns. (Primary driver of the company's top-line growth, indicating market demand for its drugs.)

Diluted EPS

Earnings per share calculated by dividing net income by the weighted-average number of diluted common shares outstanding, including the effect of all dilutive potential common shares. (Measures the profitability on a per-share basis, reflecting the impact of all outstanding potential shares.)

Cash and cash equivalents

Highly liquid investments with maturities of three months or less at the time of purchase, including cash on hand, bank deposits, and short-term marketable securities. (Indicates the company's short-term financial health and ability to meet immediate obligations and fund operations.)

Net cash provided by operating activities

The net amount of cash generated or used by the company's normal business operations during a period. (A key indicator of the company's ability to generate cash from its core business, essential for sustainability and growth.)

Year-Over-Year Comparison

Catalyst Pharmaceuticals has demonstrated significant year-over-year improvement. Total revenue for the nine months ended September 30, 2025, grew by 24.7% to $436.38 million, driven by product sales. Net income saw a substantial increase of 49.7% to $161.63 million, with diluted EPS rising to $1.27 from $0.87. The company's cash position has also strengthened considerably, reflecting robust operating cash flow generation.

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share CPRX NASDAQ Capital Marke

Filing Documents

• cprx-20250930.htm (10-Q) — 2544KB
• cprx-ex31_1.htm (EX-31.1) — 14KB
• cprx-ex31_2.htm (EX-31.2) — 14KB
• cprx-ex32_1.htm (EX-32.1) — 11KB
• cprx-ex32_2.htm (EX-32.2) — 11KB
• 0001193125-25-266854.txt ( ) — 11435KB
• cprx-20250930.xsd (EX-101.SCH) — 1366KB
• cprx-20250930_htm.xml (XML) — 2420KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS Consolidated balance sheets at September 30, 2025 (unaudited) and December 31, 2024 3 Consolidated statements of operations and comprehensive income for the three and nine months ended September 30, 2025 and 2024 (unaudited) 4 Consolidated statements of changes in stockholders' equity for the three and nine months ended September 30, 2025 and 2024 (unaudited) 5 Consolidated statements of cash flows for the nine months ended September 30, 2025 and 2024 (unaudited) 7 Notes to unaudited consolidated financial statements 8 Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 35 Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK 50 Item 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 50

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 51 Item 1A.

RISK FACTORS

RISK FACTORS 51 Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 51 Item 3. DEFAULTS UPON SENIOR SECURITIES 52 Item 4. MINE SAFETY DISCLOSURE 52 Item 5. OTHER INFORMATION 52 Item 6. EXHIBITS 53

SIGNATURES

SIGNATURES 54 2 Table of Contents CATALYST PHARMACEUTICALS, INC. CONSOLIDATED BALA NCE SHEETS (in thousands, except share data) September 30, 2025 December 31, 2024 (unaudited) ASSETS Current Assets: Cash and cash equivalents $ 689,892 $ 517,553 Accounts receivable, net 106,409 65,476 Inventory, net 28,029 19,541 Prepaid expenses and other current assets 28,123 21,039 Total current assets 852,453 623,609 Operating lease right-of-use asset, net 2,010 2,230 Property and equipment, net 1,077 1,354 License and acquired intangibles, net 128,639 156,672 Deferred tax assets, net 48,256 45,982 Investment in equity securities 19,167 21,564 Total assets $ 1,051,602 $ 851,411 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 9,096 $ 16,593 Accrued expenses and other liabilities 119,639 104,085 Total current liabilities 128,735 120,678 Operating lease liability, net of current portion 2,461 2,786 Other non-current liabilities 161 315 Total liabilities 131,357 123,779 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock, $ 0.001 par value, 5,000,000 shares authorized: none issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value, 200,000,000 shares authorized; 123,264,583 shares and 120,879,099 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 123 121 Additional paid-in capital 473,333 442,286 Retained earnings 446,789 285,161 Accumulated other comprehensive income (loss) (Note 4) — 64 Total stockholders' equity 920,245 727,632 Total liabilities and stockholders' equity $ 1,051,602 $ 851,411 The accompanying notes are an integral part of these consolidated financial statements. 3 Table of Contents CATALYST PHARMACEUTICALS, INC. CONSOLIDATED STATEMEN

View Full Filing

View this 10-Q filing on SEC EDGAR